Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.35 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | SLC6A1 | P30531 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21230424 | 1.00 | CYP2C19 (0.42) | CYP2C19FFAR3AKR1C1USP2ALDH1A1 | |
| SCHEMBL30199190 | 0.97 | — | — | |
| SCHEMBL2031585 | 0.97 | — | — | |
| SCHEMBL30480315 | 0.91 | — | — | |
| SCHEMBL988825 | 0.91 | — | — | |
| SCHEMBL22867 | 0.84 | — | — | |
| Hydrochloric Acid SCHEMBL8937886 | 0.81 | — | — | |
| SCHEMBL28822522 | 0.77 | FFAR3 (0.35) | FFAR3AKR1C1 | |
| SCHEMBL31276628 | 0.77 | FFAR3 (0.35) | FFAR3AKR1C1 | |
| SCHEMBL10872502 | 0.77 | CYP2C19 (0.32) | CYP2C19USP2ALDH1A1LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2608669-A1 | NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2013-07-03 | — | — | EP | claimed |
| WO-2012027236-A1 | NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | SCHERING CORPORATION (US) | 2012-03-01 | — | — | WO | claimed |
| CN-101098871-A | Novel spirotropane compounds and methods for the modulation of chemokine receptor activity | VIROCHEM PHARMA INC (CA) | 2008-01-02 | — | — | CN | claimed |
| CN-101001860-A | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (CH) | 2007-07-18 | — | — | CN | claimed |
| EP-1521828-A2 | PRODUCTION OF POLYKETIDES | Biotica Technology Limited (GB) | 2005-04-13 | — | — | EP | claimed |
| WO-2004007709-A2 | PRODUCTION OF POLYKETIDES | BIOTICA TECHNOLOGY LIMITED (GB) | 2004-01-22 | — | — | WO | claimed |
| CN-112189010-B | Triazole N-linked carbamoyl cyclohexyl acid as LPA antagonists | 百时美施贵宝公司 | 2026-05-15 | — | — | CN | disclosed |
| WO-2026090300-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| EP-4724437-A1 | METHODS OF TREATING INFLAMMATORY DISEASES | Interline Therapeutics, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| US-20260091026-A1 | METHODS OF TREATING INFLAMMATORY DISEASES | INTERLINE THERAPEUTICS INC (US) | 2026-04-02 | — | — | US | disclosed |
| US-20250145595-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | UNITED STATES GOVERNMENT | 2025-05-08 | — | — | US | disclosed |
| WO-2025072539-A1 | AMINO ACID COMPOUNDS WITH NITROGEN LINKERS AND USES THEREOF | PLIANT THERAPEUTICS, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| US-20250057815-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2025-02-20 | — | — | US | disclosed |
| CN-101001860-A | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (CH) | 2007-07-18 | — | — | CN | disclosed |
| US-20060078980-A1 | Production of polyketides and other natural products | GREGORY MATTHEW A | 2006-04-13 | — | — | US | disclosed |
| US-20050272132-A1 | Production of polyketides and other natural products | BIOTICA TECHNOLOGY LIMITED (GB) | 2005-12-08 | — | — | US | disclosed |
| CN-1642913-A | Piperidine or 8-aza-bicyclo[3.2.1]oct-3-yl derivatives useful as modulators of chemokine receptor activity (especially CCR5) | ASTRAZENECA AB (SE) | 2005-07-20 | — | — | CN | disclosed |
| EP-1521828-A2 | PRODUCTION OF POLYKETIDES | Biotica Technology Limited (GB) | 2005-04-13 | — | — | EP | disclosed |
| WO-2004007709-A2 | PRODUCTION OF POLYKETIDES | BIOTICA TECHNOLOGY LIMITED (GB) | 2004-01-22 | — | — | WO | disclosed |
| US-4555370-A | CYANTATION OF ACYL. FLUORIDE | BAYER AKTIENGESELLSCHAFT (DE) | 1985-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091026-A1 | METHODS OF TREATING INFLAMMATORY DISEASES | NR3C1, NR3C2, CCR1 | CYP2C19 864/4885FFAR3 258/4885AKR1C1 104/4885 |
| US-20250145595-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM4, CHRM3, CHRM5 | CYP2C19 1671/4885FFAR3 247/4885AKR1C1 861/4885 |
| US-20250057815-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | LPAR3, LPAR1, LPAR2 | CYP2C19 1493/4885FFAR3 8/4885AKR1C1 1377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.